InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,216.22
(
0.04%
)
US TECH 100
17,679.60
(
0.22%
)
Dow Jones
39,459.78
(
0.18%
)
Brent Oil
82.72
(
-1.47%
)
Bitcoin
60,542.50
(
-3.97%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 110

Thursday, 04/19/2018 1:51:07 PM

Thursday, April 19, 2018 1:51:07 PM

Post# of 438
DVAX released Ph1B/2 data from its melanoma study.

At best, the drug's value will be as a combination therapy

More data will be released at ASCO 6/1-5.

For now, everything rides on Hepislav commercialization efforts.

The likelihood is that operating costs will be ~ $160mn for 2018. As long as Hepislave revenues project out at less than $40mn, this is a probably a short candidate.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up